Filing Details

Accession Number:
0001209191-23-006371
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-02 18:13:45
Reporting Period:
2023-01-31
Accepted Time:
2023-02-02 18:13:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1435049 Chinook Therapeutics Inc. KDNY Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1823187 James Andrew King C/O Chinook Therapeutics, Inc.
400 Fairview Ave. No., 9Th Floor
Seattle WA 98109
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-31 8,333 $0.00 18,325 No 4 M Direct
Common Stock Disposition 2023-01-31 3,244 $24.68 15,081 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unirt Disposition 2023-01-31 8,333 $0.00 8,333 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2023-01-31 104,000 $0.00 104,000 $25.27
Common Stock Restricted Stock Unit Acquisiton 2023-01-31 26,000 $0.00 26,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
16,667 No 4 M Direct
104,000 2033-01-30 No 4 A Direct
26,000 No 4 A Direct
Footnotes
  1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  3. Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
  4. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
  5. The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  6. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.